Physician profile
Samuel E Day
NPI 1811304652
$2,932.69
in general payments reported to CMS, 2019-2025
41 companies · $551 in 2025
The $551 reported for 2025 was more than what 76% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $182 · 2020: $151 · 2021: $131 · 2022: $165 · 2023: $880 · 2024: $871 · 2025: $551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,303.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,303.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $291.80 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $244.51 | 2022-2025 | Imfinzi, Enhertu, Lynparza |
| Novartis Pharmaceuticals Corporation | $185.21 | 2023-2025 | |
| Progenics Pharmaceuticals, INC. | $177.79 | 2023-2025 | Pylarify |
| Boston Scientific Corporation | $159.92 | 2021-2024 | Spaceoar Vue System - 10ml |
| Regeneron Healthcare Solutions, INC. | $141.87 | 2023-2024 | Libtayo |
| Advanced Accelerator Applications | $140.03 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $133.26 | 2022-2025 | |
| Incyte Corporation | $130.37 | 2022-2025 | Jakafi, Zynyz, Monjuvi |
| Elekta, INC. | $100.18 | 2020 | |
| Intuitive Surgical, INC. | $89.69 | 2023 | Da Vinci Surgical System |
| Karyopharm Therapeutics INC. | $80.27 | 2023-2024 | Xpovio |
| Sumitomo Pharma America, INC. | $76.40 | 2023-2024 | Orgovyx |
| Pfizer INC. | $75.77 | 2024 | |
| Siemens Medical Solutions USA, INC. | $64.68 | 2023 | Halcyon |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $58.65 | 2023-2024 | Rybrevant, Tecvayli, Talvey |
| Seagen INC. | $49.70 | 2023 | Adcetris, Tukysa |
| Genzyme Corporation | $49.26 | 2023 | |
| Abbvie INC. | $49.18 | 2024-2025 | |
| Telix Pharmaceuticals | $46.81 | 2024 | Illuccix |
| Daiichi Sankyo INC. | $40.76 | 2024 | Vanflyta, Enhertu |
| Amgen INC. | $35.08 | 2023 | Lumakras, Xgeva, Vectibix |
| Takeda Pharmaceuticals U.S.A., INC. | $33.55 | 2025 | Fruzaqla |
| Blueprint Medicines Corporation | $32.58 | 2023-2024 | Ayvakit, Gavreto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.32 | 2023 | Gilotrif |
| Rigel Pharmaceuticals, INC. | $30.83 | 2025 | Tavalisse, Rezlidhia, Gavreto |
| Melinta Therapeutics, LLC | $29.86 | 2019 | |
| Geron Corporation | $29.46 | 2025 | Rytelo |
| Beigene USA, INC. | $27.60 | 2024 | Brukinsa |
| Fresenius Kabi USA, LLC | $26.47 | 2024 | Stimufend |
| Jazz Pharmaceuticals INC. | $25.13 | 2024 | |
| Caris Mpi, INC. | $24.33 | 2025 | Mi Cancer Seek |
| G1 Therapeutics, INC. | $24.08 | 2023 | Cosela |
| Myovant Sciences INC. | $23.23 | 2022 | |
| Genentech USA, INC. | $21.31 | 2023 | Rozlytrek, Tecentriq, Gavreto |
| Kite Pharma, INC. | $20.37 | 2025 | Yescarta |
| Gt Medical Technologies, INC | $20.00 | 2021 | |
| Sobi, INC | $17.06 | 2025 | |
| Blue Earth Diagnostics | $15.35 | 2025 | Posluma |
| Myriad Genetic Laboratories, INC. | $14.97 | 2020 | |
| Lilly USA, LLC | $14.46 | 2023 | Jaypirca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Day listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.